Cisplatin, dacarbazine, and fotemustine plus interferon α in patients with advanced malignant melanoma: A multicenter phase II study of the Southern Italy Cooperative Oncology Group

Cancer

Volumn 89, Issue 12, 2000, Pages 2630-2636

  Daponte, Antonio ^a   Ascierto, Paolo A ^a   Gravina, Adriano ^a   Melucci, Maria Teresa ^a   Palmieri, Giuseppe ^b   Comella, Pasquale ^c   Cellerino, Riccardo ^d   Delena, Mario ^e   Marini, Giovanni ^e   Comella, Giuseppe ^e  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Institute of Molecular Genetics   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^e Division of Medical Oncology   (Italy)

Author keywords

Cisplatin; Dacarbazine; Fotemustine; Interferon ; Melanoma

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; DACARBAZINE; FOTEMUSTINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; DRUG SAFETY; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; ANTIGENS, CD; ANTIGENS, CD146; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DACARBAZINE; FEMALE; FEVER; FOLLOW-UP STUDIES; HUMANS; INTERFERON-ALPHA; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NAUSEA; NEOPLASM PROTEINS; NEURAL CELL ADHESION MOLECULES; NEUTROPENIA; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0034672002     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20001215)89:12<2630::AID-CNCR16>3.0.CO;2-Z     Document Type: Article

References (32)

1. Chemotherapy of malignant melanoma
2. DTIC (NSC-45388) in malignant melanoma: A perspective
3. Nitrosoureas in the management of disseminated malignant melanoma
4. The nitrosoureas. An outline of clinical schedules and toxic effects
5. Final report of the French multicenter Phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases
6. Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Group
7. Fotemustine plus dacarbazine for malignant melanoma
8. Diaminodichloroplatinum: A Phase I study showing responses in testicular and other tumors
9. Phase II trial of carboplatin in advanced malignant melanoma
10. Vinblastine infusion, bleomycin and cischlorodiammineplatinum chemotherapy in metastatic melanoma
11. Vinblastine, bleomycin and cis-platinum in the treatment of metastatic malignant melanoma
12. Dacarbazine, vindesine and cisplatinum combination in advanced malignant melanoma
13. Combination of cisplatinum, vindesine and dacarbazine in advanced malignant melanoma: A Phase II study of the EORTC Malignant Melanoma Cooperative Group
14. A prospective evaluation of a triple drug regimen containing cisplatin, vinblastine and DTIC (CVD) for metastatic melanoma
15. Multicentre randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alpha 2a in the treatment of advanced melanoma
16. Improved results with the addition of interferon alpha 2b to dacarbazine in the treatment of patients with metastatic malignant melanoma
17. Fotemustine and dacarbazine plus recombinant interferon alpha 2a in the treatment of advanced melanoma
18. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
19. Primary structure of the human melanoma-antigen p97 (melanotransferrin) deduced from the mRNA sequence
20. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily
21. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
22. PCR-based detection of circulating melanoma cells as an effective marker of tumor progression
23. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay
24. Melanoma-associated antigens as messenger RNA detection markers for melanoma
25. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
26. Reporting results on cancer treatment
27. Non-parametric estimation from incomplete observations
28. Optimal two-stage designs for Phase II clinical trials
29. Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma
30. Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma
31. Phase III trial of dacarbazine versus dacarbazine with interferon α-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon α-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group Study